Protease inhibitors in potential drug development for leishmaniasis

Indian Journal of Biochemistry and Biophysics

Volumn 50, Issue 5, 2013, Pages 363-376

  Das, Partha ^a   Alam, Md Nur ^a   Paik, Dibyendu ^a   Karmakar, Kanchan ^a   De, Tripti ^b   Chakraborti, Tapati ^a  

^a UNIVERSITY OF KALYANI   (India)

^b INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

Biochemical pathways; Chemotherapy; Drug targets; Inhibitors; Leishmania; Leishmaniasis; Proteases

Indexed keywords

ANTIPROTOZOAL AGENT; PROTEINASE INHIBITOR;

DRUG DEVELOPMENT; DRUG EFFECT; LEISHMANIA; LEISHMANIASIS; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; REVIEW;

ANTIPROTOZOAL AGENTS; DRUG DISCOVERY; LEISHMANIA; LEISHMANIASIS; MOLECULAR TARGETED THERAPY; PROTEASE INHIBITORS;

PROTOZOA;

EID: 84886708999     PISSN: 03011208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (162)

1. Alvar J, Velez I D, Bern C, Herrero M, Desjeux P, Cano J, Jannin J & den Boer M (2012) Leishmaniasis worldwide and global estimates of its incidence. PloS One 7, e35671-e356712
2. Singh S P, Malaviya P, Gidwani K, Singh R P & Sundar S (2012) Visceral Leishmaniasis in Rural Bihar. Ind Emerg Infect Dis 18, 1662-1664
3. Bhunia G S, Kesari S, Chatterjee N, Kumar V & Das P (2012) The Burden of Visceral Leishmaniasis in India: Challenges in Using Remote Sensing and GIS to Understand and Control. ISRN Infect Dis 2013, http://dx.doi.org/10.5402/ 2013/675846
4. Sharma U & Singh S (2012) Immunobiology of leishmaniasis. Indian J Exp Biol 47, 412-423
5. Bhargava P & Singh R (2012) Developments in Diagnosis and Antileishmanial Drugs. Interdisciplinary Perspectives on Infectious Diseases. Interdiscip Perspect Infect Dis 2012, doi:10.1155/2012/626838
6. Monzote L (2009) Current Treatment of Leishmaniasis: A Review. Open Antimicrob Agents 1, 9-19
7. Pandey K, Sinha P K, Das V R, Bimal S, Singh S K & Das P (2009) Pharmacotherapeutic Options for Visceral Leishmaniasis-Current Scenario. Clin Med Pathol 2, 1-4
8. Zucca M & Savoia D (2011) Current Developments in the Therapy of Protozoan Infections. Open Med Chem J 5, 4-10
9. Singh N, Kumar M & Singh R K (2012) Leishmaniasis: Current status of available drugs and new potential drug targets. Asi Paci J Trop Med 5, 485-497
10. Karin S (2011) Structures, Targets and Recent Approaches in Anti-Leishmanial Drug Discovery and Development. Open Med Chem J 5, 31-39
11. Chang K P & McGwire B S (2002) Molecular determinants and regulation of Leishmania virulence. Kinetoplastid Biol Dis 1, 1-7
12. Matlashewski G (2001) Leishmania infection and virulence. Med Microbiol Immunol 190, 37-42
13. Vermelho A B, Branquinha M H, D'Ávila-Levy C M, Santos A L S, de Souza Dias E P & de Melo A C N (2010) Biological Roles of Peptidases in Trypanosomatids. Open Parasitol J 4, 5-23
14. Olivier M & Hassani K (2010) Protease inhibitors as prophylaxis against leishmaniasis: new hope from the major surface protease gp63. Future Med Chem 2, 539-542
15. Olivier M, Atayde V D, Isnard A, Hassani K & Shio M T (2012) Leishmania virulence factors: focus on the metalloprotease GP63. Microbes and Infection 14, 1-13
16. Lima A P, Reis F C & Costa T F (2013) Cysteine Peptidase Inhibitors in Trypanosomatid Parasites. Curr Med Chem 20, 3152-3173
17. Besteiro S, Williams R A M, Coombs G H & Mottram J C (2007) Protein turnover and differentiation in Leishmania. Int J Parasitol 37, 1063-1075
18. Ivens A C, Peacock, C S & Worthey E A (2005) The genome of the kinetoplastid parasite, Leishmania major. Science 309, 436-442
19. Shukla A K, Singh B K, Patra S & Dubey V K (2010) Rational approaches for drug designing against leishmaniasis. Appl Biochem Biotechnol 160, 2208-2218
20. McConville M J & Naderer T (2011) Metabolic Pathways Required for the Intracellular Survival of Leishmania. Annu Rev Microbiol 6, 543-561
21. Chawla B & Madhubala R (2010) Drug targets in Leishmania. J Parasit Dis 34, 1-13
22. Chandra S, Ruhela D, Deb A & Vishwakarma R A (2010) Glycobiology of the Leishmania parasite and emerging targets for antileishmanial drug discovery. Expert Opin Ther Targets 14,739-757
23. Goto Y, Bhatia A, Raman V, Vidal S, Bertholet S, Coler R, Howard R & Reed S (2009) Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L.major infection. Vaccine 27, 2884-2890
24. Saunders E C, D E Souza D P, Naderer T, Sernee M F, Ralton J E, Doyle M, Macrae J I, Chambers J L, Heng J, Nahid A, Likic V A & McConville M J (2010) Central carbon metabolism of Leishmania parasites. Parasitology 137, 1303-1313
25. Fernandes Rodrigues J C, Concepcion J L, Rodrigues C, Caldera A, Urbina J A & de Souza W (2008) In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects. Antimicrob Agents Chemother 52, 4098-4114
26. Magaraci F, Jimenez C J, Rodrigues C, Rodrigues J C, Braga M V, Yardley V, de Luca-Fradley K, Croft S L, de Souza W, Ruiz-Perez L M, Urbina J, Gonzalez P D & Gilbert I H (2003) Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. J Med Chem 46, 4714-4727
27. Lorente S O, Rodrigues J C, Jimenez J C, Joyce-Menekse M, Rodrigues C, Croft S L, Yardley V, de Luca-Fradley K, Ruiz-Perez L M, Urbina J, de Souza W, Gonzalez P D & Gilbert I H (2004) Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob Agents Chemother 48, 2937-2950
28. Carter N S, Yates P, Arendt C S, Boitz J M & Ullman B (2008) Purine and pyrimidine metabolism in Leishmania. Adv Exp Med Biol 625, 41-54
29. Kager P A, Rees P H, Wellde B T, Hockmeyer W T & Lyerly W H (1981) Allopurinol in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 75, 556-559
30. Loiseau P M & Bories C (2006) Mechanisms of drug action and drug resistance in Leishmania as basis for therapeutic target identification and design of Antileishmanial modulators. Curr Top Med Chem 6, 539-550
31. Castillo E, Dea-Ayuela M A, Bolás-Fernández F, Rangel M & González-Rosende M E (2010) The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives. Curr Med Chem 17, 4027-4051
32. Almeida O L & Santos J B (2011) Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review. An Bras Dermatol 86, 497-506
33. Traves J, Quaissi A, Lin P K, Tomas A & Cordeiro-da-Silva A (2005) Differential effects of polyamine derivative compounds against Leishmania infantum promastigotes and axenic amastigotes. Int J Parasitol 35, 637-646
34. Vannier-Santos M A, Menezes D, Oliviera M F & de Mello F G (2008) The putrescine analogue 1, 4-diamino-2-butanone affects polyamine synthesis, transport, ultrastructure and intracellular survival in Leishmania amazonensis. Microbiol 15, 3104-3111
35. Heby O, Persson L & Rentala M (2007) Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis. Amino Acids 33, 359-366
36. Reguera R M, Tekwani B L & Balana-Fouce R (2005) Polyamine transport in parasites: a potential target for new antiparasitic drug development. Comp Biochem Physiol C Toxicol Pharmacol 140, 151-164
37. Ilgoutz S C, Mullin K A, Southwell B R & McConville M J (1999) Glycosylphosphatidylinositol biosynthetic enzymes are localized to a stable tubular subcompartment of the endoplasmic reticulum in Leishmania mexicana. EMBO J 18, 3643-3654
38. Smith T K, Sharma D K, Crossman A, Brimacombe J S & Ferguson M A (1999) Selective inhibitors of the glycosylphosphatidylinositol biosynthetic pathway of Trypanosoma brucei. EMBO J 18, 5922-5930
39. Ferguson M A, Brimacombe J S, Brown J R, Crossman A, Dix A, Field R A, Guther M L, Milne K G, Sharma D K & Smith T K (1999) The GPI biosynthetic pathway as a therapeutic target for African sleeping sickness. Biochim Biophys Acta 1455, 327-340
40. Krauth-Siegel L R, Comini M A & Schlecker T (2007) The trypanothione system. Subcell Biochem 44, 31-51
41. Ascenzi P, Bocedi A, Visca P, Antonini G & Gradoni L (2003) Catalytic properties of cysteine proteinases from Trypanosoma cruzi and Leishmania infantum: a pre-steady-state and steady-state study. Biochem Biophys Res Commun 309, 659-665
42. Ben Khalaf N, Muylder G D, Louzir H, McKerrow J & Chenik M (2011) Leishmania major protein disulfide isomerase as drug target. Parasitol Res 110, 1911-1917
43. Veras P, Barral A, Queiroz A, Ramos A, Balestieri F & Brodskyn C (1999) A dhfr-ts-Leishmania major knockout mutant cross-protect against Leishmania amazonensis. Mem Inst Oswaldo Cruz 94, 491-496
44. Zuccotto F, Martin A C, Laskowski R A, Thornton J M & Gilbert I H (1998) Dihydrofolate reductase: a potential drug target in trypanosomes and Leishmania. J Comput Aided Mol Des 12, 241-257
45. Kuntz I (1992) Structure based strategies for drug design and discovery. Science 257, 1078-1082
46. Chauhan S C & Madhubala R (2009) Glyoxalase I gene deletion mutants of Leishmania donovani exhibit reduced methylglyoxal detoxification. PLoS One 4, e6805
47. Doerig C, Meijer L & Mottram J C (2002) Protein kinases as drug targets in parasitic protozoa. Trends Parasitol 18, 366-371
48. Mottram J, Kinnard J, Shiels B, Tait A & Barry J (1996) A novel cdc-related protein Kinases from Leishmania mexicana, LmmCRKI is post-translationally regulated during the life cycle. J Biol Chem 268, 21044-21052
49. Grant K M, Dunion M H, Yardley V, Skaltsounis A L, Marko D & Eisenbrand G (2004) Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and Antileishmanial activity. Antimicrob Agents Chemother 48, 3033-3042
50. Hassan P, Fergusson D, Grant K M & Mottram J C (2001) The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana. Mol Biochem Parasitol 113, 189-198
51. Xingi E, Smirlis D, Myrianthopoulos V, Prokopios M, Grant K & Meijer L (2009) 6-Br-5methylindirubin-3' oxime (5-Me-6-Bio) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis. Int J Parasitol 39, 1289-130
52. Weise M, Wang Q & Gorcke I (2004) Identification of mitogen activated homologues from Leishmania maxicana. Int J Parasitol 33, 1577-1587
53. Weise M (2007) Leishmania MAP Kinase: Familiar protein in unusal context. Int J Parasitol 37, 1053-1062
54. Weise M (2001) Homologues of LmPK, a mitogen activated protein kinase from Leishmania maxicana, in different Leishmania species. Med Microbiol Immunol 190, 19-22
55. Schneider E, Hsiang Y & Liu L (1991) Dna tropoisomerases as antitumor drug targets. Adv Pharamocol 21, 149-183
56. Heisig P (2001) Inhibitors of bacterial tropoisomerases: Mechanism of action and resistance and clinical aspects. Planta Med 67, 3-12
57. Das A, Dasgupta A, Sengupta T & Majumder H K (2004) Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets. Trends Parasitol 20, 381-387
58. Das B B, Sen N, Dasgupta S B, Ganguly A, Das R & Majumder H K (2006) Topoisomerase research of kinetoplastid parasite Leishmania, with special reference to development of therapeutics. Ind J Med Res 123, 221-232
59. Chowdhury A R, Mandal S, Goswami A, Ghosh M, Mandal L, Chakraborty D (2003) Dihydrobetulinic acid induces apoptosis in Leishmania donovani by primarily targeting DNA topoisomerase I and II: implications in antileishmanial therapy. Mol Med 9, 26-36
60. Roy A, Chowdhury S, Sengupta S, Mandal M & Jaisankar P (2011) Development of Derivatives of 3, 39-Diindolylmethane as Potent Leishmania donovani Bi-Subunit Topoisomerase IB Poisons. PLoS ONE 6, e28493
61. Chowdhury S, Mukherjee T, Mukhopadhyay R, Mukherjee B, Sengupta S, Chattopadhyay S, Jaisankar P, Roy S & Majumder H K (2012) The lignan niranthin poisons Leishmania donovani topoisomerase IB and favours a Th1 immune response in mice. EMBO Mol Med 4, 1126-1143
62. Banerjee B, Sen N & Majumder H K (2011) Identification of a Functional Type IA Topoisomerase, LdTopIIIβ, from Kinetoplastid Parasite Leishmania donovani. Enzyme Res 2011, 230542 doi:10.4061/2011/230542
63. Kosec G, Alvarez V E, Aguero F, Dolinar M, Turk B & Turk V (2006) Metacaspases of Trypanosoma cruzi: possible candidates for programmed cell death mediators. Mol Biochem Parasitol 145, 18-28
64. Meslin B, Zalila H, Fasel N, Picot S & Bienvenu A (2011) Are protozoan metacaspases potential parasite killers. Parasites & Vectors 4, 26
65. Gonza'lez I, Desponds C, Schaff C d, Mottram J & Fasel N (2007) Leishmania major metacaspase can replace yeast metacaspase in programmed cell death and has arginine- specific cysteine peptidase activity. Int J Parasitol 37, 161-172
66. Denise H, Poot J, Jimenez M, Ambit A, Herrmann D C & Vermeulen A N (2006) Studies on the CPA cysteine peptidase in the Leishmania infantum genome strain. JPCM5 BMC Mol Biol 7, 42
67. McKerrow H J, Doyle S P, Engel C J, Podust M L, Robertson A S, Ferreira R, Saxton T, Arkin M, Kerr D I, Brinen S L & Craik S C (2009) two approaches to discovering and developing new drugs for Chagas disease. Mem Inst Oswaldo Cruz 104, 263-269
68. Fear G, Komarnytsky S & Raskin I (2007) Protease inhibitors and their peptidomimetic derivatives as potential drugs. Pharmacol Ther 113, 354-368
69. Drag M & Salvesen G S (2010) Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 9, 690-701
70. Sabotič J & Kos J (2012) Microbial and fungal protease inhibitors-current and potential applications Appl Microbiol Biotechnol 93, 1351-1375
71. Cazzulo J J (2002) Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Chagas disease. Curr Top Med Chem 2, 1261-1271
72. Turk B (2006) Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5, 785-799
73. Drag M & Salvesen G S (2010) Emerging principles in protease-based drug discovery. Nat Rev Drug Discov 9, 690-701
74. Santos A L S (2011) Protease expressions by microorganisms and its relevance to crucial physiological/pathological events. World J Biol Chem 2, 48-58
75. Safavi E & Rostami A (2012) Role of serine proteases in inflammation: Bowman-Birk protease inhibitor (BBI) as a potential therapy for autoimmune diseases. Exp Mol Pathol 93, 428-433
76. Selzer P M, Pingel S & Hsieh I (1999) Cysteine protease inhibitors as chemotherapy: Lessons from a parasite target. Proc Natl Acad Sci USA 96, 11015-11022
77. McKerrow J H, Rosenthal P J, Swenerton R & Doyle P (2008) Development of protease inhibitors for protozoan infections. Curr Opin Infect Dis 21, 668-672
78. EI-Gayar E K (2012) Cysteine Protease Inhibitors and Parasitic Diseases. PUJ 5, 105-120
79. Otlewski J, Krowarsch D & Apostoluk W (1999) Protein inhibitors of serine proteinases. Acta Biochim Pol 46, 531-565
80. Krowarsch D, Cierpicki T, Jelen F & Otlewski J (2003) Canonical protein inhibitors of serine proteases. Cell Mol Life Sci 60, 2427-2444
81. McKerrow J H, Engel J C & Caffrey C R (1999) Cysteine protease inhibitors as chemotherapy for parasitic infections. Bioorg Med Chem 7, 639-644
82. Santos A L S, d'Avila-Levy C M, Dias F A, Ribeiro R O, Pereira F M, Elias C G, Souto-Padrón T, Lopes A H, Alviano C S, Branquinha M H & Soares R M (2006) Phytomonas serpens: cysteine protease inhibitors interfere with growth, ultrastructure and host adhesion. Int J parasitol 36, 47-56
83. Bhattacharyya A & Babu C R (2010) Purification and biochemical characterization of a serine protease inhibitor from Derris trifoliate Lour. Seed: Insight into structural and antimalarial features. Phytochem 70, 703-712
84. Teo C F, Zhou X W, Bogyo M & Carruthers V B (2007) Cysteine Protease Inhibitors Block Toxoplasma gondi Microneme Secretion and Cell Invasion. Antimicrob Agents Chemother 51, 679-688
85. McKerrow J H, McGrath M E & Engel J C (1995) The cysteine protease of Trypanosoma cruzi as a model for antiparasite drug design. Parasitology Today. 11, 279-282
86. Rogers K E, Keränen H, Durrant J D, Ratnam J, Doak A, Arkin M R & McCammon J A (2012) Novel cruzain inhibitors for the treatment of Chagas' disease. Chem Biol Drug Des 80, 398-405
87. Waag T, Gelhaus C, Rath J, Stich A, Leippe M & Schirmeister T (2010) Allicin and derivatates are cysteine protease inhibitors with antiparasitic activity. Bioorg Med Chem Lett 20, 5541-5543
88. Lavrado J, Mackey Z, Hansell E, McKerrow J H, Paulo A & Moreira R (2012) Antitrypanosomal and cysteine protease inhibitory activities of alkyldiamine cryptolepine derivatives. Bioorg Medi Chem Lett 22, 6256-6260
89. Abdulla M H, Lim K C & Sajid M (2007) Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PloS Med 4, e14
90. McGrath M E, Eakin A E, Engel J C, McKerrow J H, Craik C S & Fletterick R J (1995) The crystal structure of cruzain: a therapeutic target for Chagas' disease. J Mol Biol 247, 251-259
91. Xing R, Addington A K & Mason R W (1998) Quantification of cathepsins b and L in cells. Biochem J 332, 499-505
92. Powers J C, Asgian J L, Ekici O D & James K E (2002) Irreversible inhibitors of serine cysteine and threonine proteases. Chem Rev 102, 4639-4750
93. Silva-Almeida M, Pereira B S, Ribeiro-Guimaraes M L & Alves C R (2012) Proteinases as virulence factors in Leishmania spp. infection in mammals. Parasites & Vectors 5, 160
94. Mottram J C, Coombs G H & Alexander J (2004) Cysteine peptidases as virulence factors of Leishmania. Curr Opin Microbiol 7, 375-381
95. Alexander J, Coombs G H & Mottram J C (1998) Leishmania Mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 161, 6794-6801
96. Mundodi V, Kucknoor A S & Gedamu L (2005) Role of Leishmania [Leishmania] chagasi amastigote cysteine protease in intracellular parasite survival: studies by gene disruption and antisense mRNA inhibition. BMC Mol Biol 6, 3
97. Mottram J C, Souza A E, Hutchison J E, Carter R, Frame M J & Coombs G H. (1996) Evidence from disruption of the lmCPB gene array of Leishmania mexicana that cysteine proteinases are virulence factors. Proc Natl Acad Sci 93, 6008-6013
98. Bryson K, Besteiro S, McGachy H A, Coombs G H, Mottram J C & Alexander (2009) Overexpression of the natural inhibitor of cysteine peptidases in Leishmania mexicana leads to reduced virulence and a Th1 response. Infect Immun 77, 2971-2978
99. Mahmoudzadeh-Niknam H & McKerrow J H (2004) Leishmania tropica: cysteine proteases are essential for growth and pathogenicity. Exp Parasitol 106, 158-63
100. Selzer P M, Pingel S, Hsieh I, Ugele B, Chan V J, Engel J C, Bogyo M, Russelli D G, Sakanari J A & McKerrow J H (1999) Cysteine protease inhibitors as chemotherapy: Lessons from a parasite target. Proc Natl Acad Sci (USA) 96, 11015-11022
101. Das L, Datta N, Bandyopadhyay S & Das P K (2001) Successful therapy of lethal murine visceral leishmaniasis with cystatin involves up-regulation of nitric oxide and a favorable T cell response. J Immunol 166, 4020-4028
102. Mukherjee S, Ukil A & Das P K (2007) Immunomodulatory peptide from cystatin, a natural cysteine protease inhibitor, against leishmaniasis as a model macrophage disease. Antimicrob Agents Chemother 51, 1700-1707
103. Kar S, Ukil A & Das P K (2009) Signaling events leading to the curative effect of cystatin on experimental visceral leishmaniasis: involvement of ERK1/2, NF-kappaB and JAK/STAT pathways. Eur J Immunol 39, 741-51
104. Besteiro S, Coombs G H & Mottram J C (2004) A potential role for ICP, a Leishmanial inhibitor of cysteine peptidases, in the interaction between host and parasite. Mol Microbiol 54, 1224-1236
105. Smith B O, Picken N C, Westrop G D, Bromek K, Mottram J C & Coombs G H (2006) The structure of Leishmania mexicana ICP provides evidence for convergent evolution of cysteine peptidase inhibitors. J Biol Chem 281, 5821-5828
106. Gontijo V S, Judice W A, Codonho B, Pereira I O, Assis D M, Januário JP, Caroselli E E, Juliano M A, de Carvalho Dosatti A, Marques M J, Viegas Junior C & Henrique dos Santos M (2012) Leishmanicidal, antiproteolytic and antioxidant evaluation of natural biflavonoids isolated from Garcinia brasiliensis and their semisynthetic derivatives. Eur J Med Chem 58, 613-623
107. Katunuma N, Matsunaga Y, Himeno K & Hayashi Y (2003) Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors. Biol Chem 384, 883-890
108. Paladi C d S, Pimental I A S, Katz S, Cunha R L O R, Judice W A D S, Caires A C F & Barbieri C L (2012) In Vitro and in Vivo Activity of a Palladacycle Complex on Leishmania (Leishmania) amazonensis. PLoS Negl Trop Dis 6, e1626
109. Pimental I A S, Paladi C d S, Katz S, Judice W A D S, Cunha R L O R & Barbieri C L (2012) In Vitro and in Vivo Activity of an Organic Tellurium Compound on Leishmania (Leishmania) chagasi. PLoS ONE 7, e48780
110. Pimentel-Elardo S M, Buback V, Gulder T A, Bugni T S, Reppart J, Bringmann G, Ireland C M, Schirmeister T & Hentschel U (2011) New tetromycin derivatives with anti-trypanosomal and protease inhibitory activities. Mar Drugs 9, 1682-1697
111. Ersfeld K, Barraclough H & Gull K (2005) Evolutionary relationships and protein domain architecture in an expanded calpain superfamily in kinetoplastid parasites. J Mol Evol 61, 742-57
112. d'Avila-Levy C M, Marinho F A, Santos L O, Martins J L, Santos A L S & Branquinha M H (2006) Antileishmanial activity of MDL 28170, a potent calpain inhibitor. Int J Antimicrob Agents 28, 138-242
113. Isnard A, Hassani K & Shio M T (2012) Impact of Leishmania metalloproteases GP63 on macrophage signaling. Front Cell Infect Microbiol 2, 1-9
114. Yao C (2010) Major Surface Protease of Trypanosomatids: One Size Fits All?. Infect Immun 78, 22-31
115. Gomez M A, Contreras I, Hallé M, Tremblay M L, McMaster R W & Olivier M (2009) Leishmania GP63 alters host signaling through cleavage-activated protein tyrosine phosphatases. Sci Signal 2, 58
116. Shio M T & Olivier M (2010) Leishmania survival mechanisms: the role of host phosphatases. J Leuko Biol 88, 1-3
117. Schlagenhauf E, Etges R & Metcalf P (1998) The crystal structure of the Leishmania major surface proteinase leishmanolysin (gp63). Structure 6, 1035-1046
118. Bangs J D, Ransom D A, Nimick M, Christie G & Hooper N M (2001) In vitro cytocidal effects on Trypanosoma bruccei and inhibition of Leishmania major GP63 by peptidomimetic metalloproteases inhibitors. Mol Biochem Parasitol 114, 111-117
119. Corradin S, Ransijn A, Corradin G, Roggero M A, Schmitz A A, Schneider P, Mauël J & Vergères G (1999) MARCKS-related protein (MRP) is a substrate for the Leishmania major surface protease leishmanolysin (gp63). J Biol Chem 274, 25411-8
120. Corradin S, Ransijn A, Corradin G, Bouvier J, Delgado M B, Fernandez-carneado J & Mottram J C, Vergea, Jacques Mauel J (2002) Novel peptide inhibitors of Leishmania gp63 based on the cleavage site of MARCKS (myristoylated alanine-rich C kinase substrate)-related protein. Biochem J 367, 761-769
121. Choudhury R, Das P, De T & Chakraborti T (2010) Immunolocalization and characterization of two novel proteases in Leishmania donovani: putative roles in host invasion and parasite development. Biochimie 92, 1274-1286
122. Baig M S, Gangwar S & Goyal N (2011) Biochemical characterization of dipeptidylcarboxypeptidase of Leishmania donovani. Cell Mol Biol (Noisy-le-grand) 57, 56-61
123. Maretti-Mira A C, de Pinho Rodrigues K M, de Oliveira-Neto M P, Pirmez C & Craft N (2011) MMP-9 activity is induced by Leishmania braziliensis infection and correlates with mucosal leishmaniasis. Acta Trop 119,160-164
124. Maretti-Mira A C, de Oliveira-Neto M P, Da-Cruz AM, de Oliveira M P, Craft N & Pirmez C (2011) Therapeutic failure in American cutaneous leishmaniasis is associated with gelatinase activity and cytokine expression. Clin Exp Immunol 163(2) 207-14
125. Costa J D, Nogueira de Melo A C, Vermelho A B, Meirelles Mde N & Porrozzi R (2008) In vitro evidence for metallopeptidase participation in hepatocyte damage induced by Leishmania chagasi-infected macrophages. Acta Trop 106,175-183
126. Geurts N, Opdenakker G & den Steen P E V (2012) Matrix metalloproteinases as therapeutic targets in protozoan parasitic infections. Pharmacol Ther 133, 257-279
127. Okwor I & Uzonna J E (2013) The immunology of Leishmania/HIV co-infection. Immunol Res 56, 163-71
128. Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, Gastaut JA, Costagliola D & Rosenthal E (2002) Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis 186, 1366-1370
129. Rosa R, Pineda JA, Delgado J, Macías J, Morillas F, Mira J A, Sánchez-Quijano A, Leal M & Lissen E. (2002) Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol 40, 762-776
130. Trudel N, Garg R, Messier N, Sundar S, Ouellette M & Tremblay M J (2008) Intracellular Survival of Leishmania Species That Cause Visceral Leishmaniasis Is Significantly Reduced by HIV-1 Protease Inhibitors. J Infect Dis 198, 1292-9
131. Kumar P, Lodge R, Trudel N, Ouellet M, Ouellette M & Tremblay M J (2010) Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes. PLoS Negl Trop Dis 4, e642
132. Valdivieso E, Rangel A, Moreno J, Saugar J M, Cañavate C, Alvar J & Dagger F (2010) Effects of HIV aspartyl-proteinase inhibitors on Leishmania spp. Exp Parasitol 126, 557-563
133. Zhang T, Maekawa Y, Yasutomo K, Ishikawa H, Fawzy Nashed B, Dainichi T, Hisaeda H, Sakai T, Kasai M, Mizuochi T, Asao T, Katunuma N & Himeno K (2000) Pepstatin A-sensitive aspartic proteases in lysosome are involved in degradation of the invariant chain and antigen-processing in antigen presenting cells of mice infected with Leishmania major. Biochem Biophys Res Commun 276, 693-701
134. Griensven J V, Diro E, Lopez-Velez R, Boelaert M, Lynen L, Zijlstra Ed, Dujardin J C & Hailu A (2013) HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals. Lancet Infect Dis 13, 251-259
135. Santos LO, Marinho FA, Altoé E F, Vitório B S, Alves C R, Britto C, Motta, M C M, Branquinha M H, Santos A L S & d'Avila-Levy C M (2009) HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis. PLoS One 4, 4918
136. Gemma S, Giovani S, Brindisi M & Tripaldi P (2012) Quinolylhydrazones as novel inhibitors of Plasmodium falciparum serine protease PfSUB1. Bioorg Med Chem Lett 22, 5317-5321
137. Montero E, Rafiq S, Heck S & Lobo C A (2007) Inhibition of human erythrocyte invasion by Babesia divergens using serine protease inhibitors. Mol Biochem Parasitol 153, 80-84
138. Witheres-Martinez C, Jean L & Blackman M J (2004) subtilisin like proteases of the malaraia parasite. Mol Microbiol 53, 55-63.
139. Krowarsch D, Cierpicki T, Jelen F & Otlewski J (2003) Canonical protein inhibitors of serine proteases. Cell Mol Life Sci 60, 2427-2444
140. Lee D H & Goldberg A L (1998) Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 8, 397-403
141. Conseil V, Soete M & Dubremetz J F (1999) Serine protease inhibitors block invasion of host cells by Toxoplasma gondii. Antimicrob Agents Chemother 46, 1358-1361
142. La Peyre J F, Xue Q G, Itoh N, Li Y & Cooper R K (2010) Cooper Serine protease inhibitor cvSI-1 potential role in the eastern oyster host defense against the protozoan parasite Perkinsus marinus. Dev Comp Immunol 34, 84-92
143. Quaezada LAL & McKerrow J H (2011) Schistosome serine protease inhibitors: parasite defense or homeostasis? Anais da Academia Brasileira de Ciências 83, 663-672
144. Motta F N, Bastos I M D, Faudry E, Ebel C, Lima M M, Neves D, Ragno M, Barbosa J A R G & de Freitas S M (2012) The Trypanosoma cruzi Virulence Factor Oligopeptidase B (OPBTc) Assembles into an Active and Stable Dimer. PLoS ONE 7, e30431
145. Morty R E, Troeberg L, Pike R N, Jones R, Nickel P, Lonsdale-Eccles J D & Coetzer T H (1998) A trypanosome oligopeptidase as a target for the trypanocidal agents pentamidine, diminazene and suramin. FEBS Lett 433, 251-256
146. Li H, Child M A & Bogyo M (2012) Proteases as Regulators of Pathogenesis: Examples from the Apicomplexa. Biochim Biophys Acta 1824, 177-185
147. Choudhury R, Das P, Bhaumik S K & Chakraborti T (2010) In situ immunolocalization and stage-dependent expression of a secretory serine protease in Leishmania donovani and its role as a vaccine candidate. Clin Vac Immunol 17, 660-667
148. Swenerton R K, Knudsen G M, Sajid M, Kelly B L & McKerrow J H (2010) Leishmania subtilisin is a maturase for the trypanothione reductase system and contributes to disease pathology. J Biol Chem 285, 31120-31129
149. Guedes H L, Pinheiro R O, Chaves S P, De-Simone S G & Rossi-Bergmann B (2010) Serine proteases of Leishmania amazonensis as immunomodulatory and disease-aggravating components of the crude LaAg. Vaccine 28, 5491-5496
150. Swenerton R K, Zhang S, Sajid M, Medzihradszky K F, Craik C S, Kelly B L & McKerrow J H (2011) The oligopeptidase B of Leishmania regulates parasite enolase and immune evasion. J Biol Chem 286: 429-440
151. Munday J C, McLuskey K, Brown E, Coombs G H & Mottram J C (2011) Oligopeptidase B deficient mutants of Leishmania major. Mol Biochem Parasitol 175, 49-57
152. Silva V M G, Larangeira D F, Oliveira P R S, Sampaio R B, Suzart P, Biointervention Student Group, Nihei J S, Teixeira M C A, Mengel J O, dos-Santos W L C & Carvalho L P (2011) Enhancement of experimental cutaneous leishmaniasis by Leishmania molecules is dependent on interleukin-4, serine protease/esterase activity, and parasite and host genetic backgrounds. Infect Immun 79, 1236-124
153. Choudhury R, Das P, De T & Chakraborti T (2013) 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity. Immunobiol 218, 114-126
154. Silva-Lopez R E, Morgado-Díaz J A, Chávez M A & Giovanni-De-Simone S (2007) Effects of serine protease inhibitors on viability and morphology of Leishmania (Leishmania) amazonensis promastigotes. Parasitol Res 101, 1627-1635
155. Pereira I O, Assis D M, Juliano M A, Cunha R L, Barbieri C L, do Sacramento L V, Marques M J & dos Santos M H (2011) Natural products from Garcinia brasiliensis as Leishmania protease inhibitors. J Medi Food 14, 557-562
156. Morrison L S, Goundry A, Faria M S, Tetley L, Eschenlauer S.C, Westrop G D, Dostalova A, Volf P, Coombs G H, Lima A P & Mottram J C (2012) Ecotin-like serine peptidase inhibitor ISP1 of Leishmania major plays a role in flagellar pocket dynamics and promastigote differentiation. Cell Microbiol 14, 1271-86
157. Eschenlauer S C, Faria M S, Morrison L S, Bland N, Ribeiro-Gomes F L, DosReis G A, Coombs G H, Lima A P, Mottram J C (2009) Influence of parasite encoded inhibitors of serine peptidases in early infection of macrophages with Leishmania major. Cell Microbiol 11, 106-120
158. Faria M S, Reis F C, Azevedo-Pereira R L, Morrison L S, Mottram J C & Lima A P (2011) Leishmania inhibitor of serine peptidase 2 prevents TLR4 activation by neutrophil elastase promoting parasite survival in murine macrophages. J Immunol 186, 411-22
159. Silva-López R E (2010) Leishmania proteases: new targets for rational drug development. Quim ova 33, 1541-1548
160. McLuskey K, Paterson N G, Bland N D, Isaacs N W & Mottram J C (2010) Crystal structure of Leishmania major oligopeptidase B gives insight into the enzymatic properties of a trypanosomatid virulence factor. J Biol Chem 285, 39249-39259
161. Bastos I M, Motta F N, Grellier P & Santana J M (2013) Parasite Prolyl Oligopeptidases and the Challenge of Designing Chemotherapeuticals for Chagas disease, Leishmaniasis and African Trypanosomiasis. Curr Med Chem 20, 3103-3115
162. Coetzer T H T, Goldring J P D & Huson L E J (2008) Oligopeptidase B: A processing peptidase involved in pathogenesis. Biochimie 90, 336-344